Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAISE-AI: rhPro-UK for Extended-Window Acute Ischemic Stroke
NCT07901842Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Recombinant Human Prourokinase Group with Matching Placebo Group (2 arms). Primary endpoint: Proportion of Participants With a Modified Rankin Scale Score of 0-1 at 90 days. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
recombinant human prourokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07901842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07901842.